Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Benzinga Newsdesk www.benzinga.com Negative 85.4%

Neg 85.4% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.